Market Overview:
The global dilated cardiomyopathy therapeutic market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of dilated cardiomyopathy, rising geriatric population, and technological advancements in the field of cardiac therapies. Based on type, the global dilated cardiomyopathy therapeutic market is segmented into aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and beta-blockers. The aldosterone antagonists segment is expected to grow at the highest CAGR during the forecast period owing to their ability to improve heart function and reduce mortality rates in patients with DCM. Based on application, the global dilated cardiomyopathy therapeutic market is segmented into hospitals and academic institutions. The hospitals segment accounted for majority share of the global Dilated Cardiomyopathy Therapeutic Market in 2017 and it is projected to maintain its dominance during forecast period as well due high adoption rate of novel therapies by healthcare professionals for treatment of DCM patients across globe .Geographically, North America dominates Global Dilated Cardiomyopathy Therapeutic Market followed by Europe .
Product Definition:
Dilated cardiomyopathy (DCM) is a heart muscle disease that causes the heart to become enlarged and weakened. This can lead to problems with blood flow and heart failure. Dilated cardiomyopathy Therapeutic is a drug that is used to treat dilated cardiomyopathy. It helps improve the function of the heart by strengthening the muscle and preventing further damage.
Aldosterone antagonists:
Aldosterone Antagonist is a type of medication that reduces the production of aldosterone by the adrenal glands. Aldosterone has an important role in maintaining fluid levels in the body as well as helping to regulate blood pressure and sodium retention. When there is too much aldosterone present in the body, it can lead to several health problems such as salt cravings, high blood pressure, potassium deficiency and others.
Angiotensin-converting enzyme (ACE) inhibitors:
The global angiotensin-converting enzyme (ACE) inhibitors and it's usage in dilated cardiomyopathy therapeutic market size was valued at USD 1.8 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The growing prevalence of heart failure, hypertension, stroke, renal dysfunction & diabetes are some major factors that drive the growth of this market globally.
Application Insights:
The hospitals segment dominated the global market in 2017. This can be attributed to factors such as a high prevalence of dilated cardiomyopathy and increasing awareness among healthcare professionals. Moreover, an increase in the adoption of advanced therapies such as heart transplantation is expected to drive revenue growth during the forecast period.
In recent years, there has been an increased focus on personalized medicine through genetic analysis which may help identify patients who are more likely to benefit from certain drugs or treatments related to dilated cardiomyopathy. For instance, it has been found that some patients with DCM respond better than others do to beta-blockers or ACE inhibitors used for treatment purposes thus providing clinicians with insights into patient subgroups that may lead towards tailoring drug therapy for specific patient groups thereby driving demand over the forecast period.
Regional Analysis:
North America dominated the global DDx dilated cardiomyopathy therapeutics market in 2017. This can be attributed to the high prevalence of this condition, increased adoption of lifestyle modifications and preventive measures, and availability of highly skilled physicians. Moreover, a higher level of patient awareness is also expected to contribute towards its large share in North America.
Asia Pacific is anticipated to grow at a lucrative rate over the forecast period owing to an increase in healthcare expenditure by governments as well as private organizations coupled with rising patient awareness levels pertaining to early diagnosis & treatment options for DDx Dilated Cardiomyopathy (DCM). Furthermore, increasing medical tourism due to affordability and availability of world-class healthcare services are some other factors driving growth in this region. In addition, favorable government initiatives such as “Hospital Efficient Rating†program implemented by The Government Of India for improving hospital infrastructure will further boost regional growth during the forecast period.
Growth Factors:
- Increasing incidence of dilated cardiomyopathy (DCM) due to growing awareness about the disease and its risk factors.
- Growing population of aging individuals who are at a higher risk for developing DCM.
- Increasing prevalence of cardiovascular diseases (CVDs) which is the leading cause of death worldwide and contributes to the development of DCM.
- Rising demand for better treatment options for managing DCM symptoms and improving patient outcomes.
- Technological advancements in cardiac care that enable earlier diagnosis and treatment of DCM patients
Scope Of The Report
Report Attributes
Report Details
Report Title
Dilated Cardiomyopathy Therapeutic Market Research Report
By Type
Aldosterone antagonists, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Beta-blockers
By Application
Hospitals, Academic Institutions
By Companies
Array BioPharma, Inc., AstraZeneca plc., Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (J&J), Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vericel Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Dilated Cardiomyopathy Therapeutic Market Report Segments:
The global Dilated Cardiomyopathy Therapeutic market is segmented on the basis of:
Types
Aldosterone antagonists, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Beta-blockers
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Academic Institutions
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Array BioPharma, Inc.
- AstraZeneca plc.
- Celladon Corporation
- GlaxoSmithKline plc
- Janssen Pharmaceuticals, Inc. (J&J)
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Vericel Corporation
Highlights of The Dilated Cardiomyopathy Therapeutic Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Aldosterone antagonists
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin II receptor blockers (ARBs)
- Beta-blockers
- By Application:
- Hospitals
- Academic Institutions
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dilated Cardiomyopathy Therapeutic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dilated cardiomyopathy is a condition in which the heart muscle becomes enlarged and weak. This can lead to difficulty breathing, heart failure, and death. Dilated cardiomyopathy is treated with medications, surgery, or a combination of both.
Some of the major players in the dilated cardiomyopathy therapeutic market are Array BioPharma, Inc., AstraZeneca plc., Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (J&J), Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vericel Corporation.
The dilated cardiomyopathy therapeutic market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dilated Cardiomyopathy Therapeutic Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dilated Cardiomyopathy Therapeutic Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dilated Cardiomyopathy Therapeutic Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dilated Cardiomyopathy Therapeutic Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dilated Cardiomyopathy Therapeutic Market Size & Forecast, 2018-2028
4.5.1 Dilated Cardiomyopathy Therapeutic Market Size and Y-o-Y Growth
4.5.2 Dilated Cardiomyopathy Therapeutic Market Absolute $ Opportunity
Chapter 5 Global Dilated Cardiomyopathy Therapeutic Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dilated Cardiomyopathy Therapeutic Market Size Forecast by Type
5.2.1 Aldosterone antagonists
5.2.2 Angiotensin-converting enzyme (ACE) inhibitors
5.2.3 Angiotensin II receptor blockers (ARBs)
5.2.4 Beta-blockers
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dilated Cardiomyopathy Therapeutic Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dilated Cardiomyopathy Therapeutic Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Academic Institutions
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dilated Cardiomyopathy Therapeutic Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dilated Cardiomyopathy Therapeutic Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dilated Cardiomyopathy Therapeutic Analysis and Forecast
9.1 Introduction
9.2 North America Dilated Cardiomyopathy Therapeutic Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dilated Cardiomyopathy Therapeutic Market Size Forecast by Type
9.6.1 Aldosterone antagonists
9.6.2 Angiotensin-converting enzyme (ACE) inhibitors
9.6.3 Angiotensin II receptor blockers (ARBs)
9.6.4 Beta-blockers
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dilated Cardiomyopathy Therapeutic Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Academic Institutions
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dilated Cardiomyopathy Therapeutic Analysis and Forecast
10.1 Introduction
10.2 Europe Dilated Cardiomyopathy Therapeutic Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dilated Cardiomyopathy Therapeutic Market Size Forecast by Type
10.6.1 Aldosterone antagonists
10.6.2 Angiotensin-converting enzyme (ACE) inhibitors
10.6.3 Angiotensin II receptor blockers (ARBs)
10.6.4 Beta-blockers
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dilated Cardiomyopathy Therapeutic Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Academic Institutions
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dilated Cardiomyopathy Therapeutic Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dilated Cardiomyopathy Therapeutic Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dilated Cardiomyopathy Therapeutic Market Size Forecast by Type
11.6.1 Aldosterone antagonists
11.6.2 Angiotensin-converting enzyme (ACE) inhibitors
11.6.3 Angiotensin II receptor blockers (ARBs)
11.6.4 Beta-blockers
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dilated Cardiomyopathy Therapeutic Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Academic Institutions
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dilated Cardiomyopathy Therapeutic Analysis and Forecast
12.1 Introduction
12.2 Latin America Dilated Cardiomyopathy Therapeutic Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dilated Cardiomyopathy Therapeutic Market Size Forecast by Type
12.6.1 Aldosterone antagonists
12.6.2 Angiotensin-converting enzyme (ACE) inhibitors
12.6.3 Angiotensin II receptor blockers (ARBs)
12.6.4 Beta-blockers
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dilated Cardiomyopathy Therapeutic Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Academic Institutions
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dilated Cardiomyopathy Therapeutic Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dilated Cardiomyopathy Therapeutic Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dilated Cardiomyopathy Therapeutic Market Size Forecast by Type
13.6.1 Aldosterone antagonists
13.6.2 Angiotensin-converting enzyme (ACE) inhibitors
13.6.3 Angiotensin II receptor blockers (ARBs)
13.6.4 Beta-blockers
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dilated Cardiomyopathy Therapeutic Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Academic Institutions
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dilated Cardiomyopathy Therapeutic Market: Competitive Dashboard
14.2 Global Dilated Cardiomyopathy Therapeutic Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Array BioPharma, Inc.
14.3.2 AstraZeneca plc.
14.3.3 Celladon Corporation
14.3.4 GlaxoSmithKline plc
14.3.5 Janssen Pharmaceuticals, Inc. (J&J)
14.3.6 Merck & Co., Inc.
14.3.7 Novartis International AG
14.3.8 Pfizer, Inc.
14.3.9 Sanofi S.A.
14.3.10 Teva Pharmaceutical Industries Ltd.
14.3.11 Vericel Corporation
